MOUNJARO (tirzepatide), a GIP/GLP-1 dual receptor agonist, improved blood glucose and body mass index in children and adolescents aged 10-18 with type 2 diabetes, according to trial results released by Eli Lilly last week.
The trial was conducted with almost 100 participants with type 2 diabetes inadequately controlled with metformin, basal insulin or both.
At 30 weeks, Mounjaro achieved superior improvements in A1C, BMI and fasting blood glucose compared to placebo, and this continued through 52 weeks in the trial's long-term extension.
A1C was reduced by an average of 2.2%, while BMI was reduced by an average of around 9%.
The main adverse events, which occurred primarily during dose escalation, were gastrointestinal-related and mild to moderate in severity.
The findings suggest that Mounjaro could provide another potential treatment for a group where options are limited.
"Youth living with type 2 diabetes often face a more aggressive disease course, and in many instances, first-line treatments like metformin and basal insulin, fail to control their A1C adequately," said lead investigator Dr Tamara Hannon from Indiana University School of Medicine.
"The [trial] results show that Mounjaro delivered significant and clinically meaningful improvements in blood sugar, BMI and fasting serum glucose in paediatric patients.
"These results offer a promising opportunity to help shift the long-term health trajectory for young people living with this complex condition."
Lilly has submitted the results to global regulatory agencies for an expanded indication to include paediatric patients.
Read the study HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Sep 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Sep 25
